Survivin, an inhibitor of apoptosis (IAP) protein, is expressed in the G2/M phase of the cell cycle in a cycle-regulated manner. At the beginning of mitosis, survivin associates with microtubules of the mitotic spindle in a specific and saturable reaction that is regulated by microtubule dynamics. Disruption of survivin-microtubule interactions results in loss of survivin′s anti-apoptosis function and increased caspase-3 activity, a mechanism involved in cell death, during mitosis. It indicates that survivin may counteract a default induction of apoptosis in G2/M phase. The overexpression of survivin in cancer may overcome this apoptotic checkpoint and favor aberrant progression of transformed cells through mitosis.
特異性
MAB4617 detects human survivin (16.5 kDa).
免疫原
Full length recombinant human survivin
アプリケーション
Research Category アポトーシス及び癌
Research Sub Category BCL2とその阻害
Detect Survivin using this Anti-Survivin Antibody, clone 8E2 validated for use in ELISA & IF.
Immunofluorescence
ELISA (for detection only)
Does not work for Western Blot
Does not work for Immunohistochemistry
Optimal working dilutions must be determined by end user.
関連事項
Replaces: MAB3509
物理的形状
Format: Purified
Purified immunoglobulin, by Protein G. Liquid in 10 mM PBS, pH 7,4 containing 0.2% BSA and 0.09% sodium azide.
保管および安定性
Maintain at 2-8°C for up to 12 months.
その他情報
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法的情報
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Pancreatic cancer (PC) is a lethal solid malignancy with resistance to traditional chemotherapy. Recently, considerable studies have demonstrated the ubiquitous antitumor properties of gene therapy mediated by the oncolytic vaccinia virus. The second mitochondrial‑derived activator of caspase (Smac) has been